CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University)

N/A

Report date: 2024/11/18 20:00:28

Base Information

Drug NameCD123/CLL1 CAR-T Cell Therapy (Fujian Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsInterleukin-3 receptor subunit alpha modulators
TargetsInterleukin-3 receptor subunit alphaC-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesFujian Medical University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFujian Medical University
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A